Dr. Daneshmand on safety of TAR-200 intravesical chemo delivery system in NMIBC

Video

Siamak Daneshmand, MD, discusses the safety profile for TAR-200 from the phase 2b SUNRISE-1 trial, which explored the novel intravesical chemo delivery system in patients with BCG-unresponsive on–muscle-invasive bladder cancer.

Siamak Daneshmand, MD, discusses the safety of the novel intravesical chemo delivery system TAR-200 in patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). TAR-200 works by providing continuous low-doses of localized gemcitabine via insertion into the bladder. At the 2023 AUA Annual Meeting, Daneshmand presented findings from the phase 2b SUNRISE-1 trial, which is exploring the safety and efficacy of TAR-200 in NMIBC.

Transcript

TAR-200 has been very well tolerated in the SUNRISE-1 trial. We’ve seen the usual grade 1 and grade 2 adverse events (AEs) in many of the patients. And the serious toxicities—the grade 3 AEs and higher—have been very, very few. So this is a very well tolerated device. The systemic uptake of the drug is very minimal to none. We're just not seeing any systemic uptake, which is exactly what we want to see. And the AEs are basically what we see in any management of any non–muscle invasive bladder cancer agents, which is the dysuria, the frequency urgency, UTIs, things like that. But again, most of those were grade 1 to 2 and we have very, very few grade 3 or higher toxicities.

Transcript has been edited for clarity.

Related Videos
Abstract blur luxury hospital corridor | Image Credit: @ zephyr_p - @ zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.